Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by Cwm LLC

Cwm LLC increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 15.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,884 shares of the company’s stock after acquiring an additional 1,035 shares during the period. Cwm LLC’s holdings in Neurocrine Biosciences were worth $908,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. RFP Financial Group LLC raised its stake in Neurocrine Biosciences by 346.5% in the first quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock valued at $26,000 after buying an additional 149 shares in the last quarter. Mather Group LLC. acquired a new stake in Neurocrine Biosciences in the first quarter valued at $26,000. Ashton Thomas Private Wealth LLC acquired a new stake in Neurocrine Biosciences in the second quarter valued at $28,000. Innealta Capital LLC purchased a new position in shares of Neurocrine Biosciences during the second quarter worth about $30,000. Finally, New Covenant Trust Company N.A. purchased a new position in shares of Neurocrine Biosciences during the first quarter worth about $32,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Neurocrine Biosciences

In other news, Director Gary A. Lyons sold 11,570 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $150.43, for a total transaction of $1,740,475.10. Following the sale, the director now owns 119,047 shares of the company’s stock, valued at $17,908,240.21. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Julie Cooke sold 12,632 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $153.26, for a total transaction of $1,935,980.32. Following the sale, the insider now owns 18,202 shares of the company’s stock, valued at $2,789,638.52. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gary A. Lyons sold 11,570 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $150.43, for a total value of $1,740,475.10. Following the completion of the sale, the director now directly owns 119,047 shares in the company, valued at approximately $17,908,240.21. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 59,968 shares of company stock valued at $8,999,632 in the last quarter. 4.30% of the stock is currently owned by corporate insiders.

Neurocrine Biosciences Trading Down 0.4 %

NASDAQ NBIX opened at $118.01 on Friday. The business’s 50 day moving average is $126.01 and its two-hundred day moving average is $134.82. Neurocrine Biosciences, Inc. has a 12-month low of $103.63 and a 12-month high of $157.98. The stock has a market capitalization of $11.88 billion, a price-to-earnings ratio of 32.51 and a beta of 0.36.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Thursday, August 1st. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.15 by ($0.52). The business had revenue of $590.20 million for the quarter, compared to analyst estimates of $545.98 million. Neurocrine Biosciences had a return on equity of 14.86% and a net margin of 16.00%. The business’s revenue for the quarter was up 30.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.95 EPS. Equities analysts forecast that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on NBIX shares. Morgan Stanley raised their price objective on Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a report on Friday, July 12th. Citigroup raised their price objective on Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. Barclays dropped their price objective on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Guggenheim raised their price objective on Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Finally, Oppenheimer raised their price objective on Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Five equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $163.91.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.